Swedish prostate cancer test to be introduced in Europe
The new Stockholm3 test, which improves prostate cancer diagnosis, gets assistance from EIT Health for a faster introduction in Europe. In a first step the test will be clinically validated in Germany, the Netherlands and Belgium. The Stockholm3 test was developed by researchers at Karolinska Institutet.
EIT Health, supported by the EU body European Innovation and Technology (EIT), will provide financing for clinical validation of the Stockholm3 test in Germany, the Netherlands and Belgium. This will be carried out together with Friedrich-Alexander-Universität, Erasmus Universitair, Academisch Ziekenhuis Groningen, Katholieke Universiteit Leuven and Universiteit Gent. The British prostate cancer foundation has previously announced that it will financially support the evaluation of the test in the British health care system.
The Stockholm3 test is a blood test that finds 20 per cent more aggressive prostate cancer while at the same time reducing the number of unnecessary biopsies by 50 per cent, compared to current clinical practice. It has been available to the Swedish healthcare since December 2016.
The Stockholm3 test combines five protein markers, over 100 genetic markers, clinical data and a decision algorithm to detect the risk of aggressive prostate cancer. The test is based on research conducted at Karolinska Institutet. It has been tried on men 50-70 years in a clinical study which included almost 60,000 participants. The results have been published in numerous scientific journals, including The Lancet Oncology, Nature Reviews Clinical Oncology and European Urology Focus.
The research to develop the Stockholm3 test was financed by the Stockholm County Council and developed in collaboration with Thermo Fisher Scientific. Professor Henrik Grönberg at Karolinska Institutet holds patent applications in the field of prostate cancer diagnostics.
For more details, visit sthlm3.se
For more information about the research, please contact:
Henrik Grönberg, MD, Professor Karolinska Institutet Phone: +46 8 52482347 or +46 70 3411356 Email: henrik.gronberg@ki.se
EIT Health is one of the largest healthcare initiatives worldwide. Its goal is to sustainably advance the fundamentals of healthcare and thus promote suitable future conditions for healthy living, active ageing and improved wellbeing of people across Europe. EIT Health leverages the expertise of more than 140 member organisations from the pharma, diagnostics and med tech fields, payers, insurances, research institutions and universities.
For more information visit: eithealth.eu
Contacts
Contact the Press Office: ki.se/pressroom
Karolinska Institutet (http://ki.se/english) is one of the world's leading medical universities. Its vision is to significantly contribute to the improvement of human health. Karolinska Institutet accounts for over 40 per cent of the medical academic research conducted in Sweden and offers the country´s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.
Subscribe to releases from Karolinska Institutet - English
Subscribe to all the latest releases from Karolinska Institutet - English by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Karolinska Institutet - English
Using social media may impair children’s attention8.12.2025 06:01:00 CET | Press Release
Children who spend a significant amount of time on social media tend to experience a gradual decline in their ability to concentrate. This is according to a comprehensive study from Karolinska Institutet, published in Pediatrics Open Science, where researchers followed more than 8,000 children from around age 10 through age 14.
POTS common in patients with long COVID3.10.2025 11:33:37 CEST | Press Release
A new study from Karolinska Institutet in Sweden shows that an unusual heart rhythm disorder, POTS, is particularly common in people with long COVID. The majority of those affected are middle-aged women. The study is published in the scientific journal Circulation: Arrhythmia and Electrophysiology.
Simple test can predict risk of severe liver disease29.9.2025 09:00:00 CEST | Press Release
A new study from Karolinska Institutet, published in the scientific journal The BMJ, shows how a simple blood analysis can predict the risk of developing severe liver disease. The method may already start to be applied in primary care to enable the earlier detection of cirrhosis and cancer of the liver.
Press invitation: Announcement of the Nobel Prize in Physiology or Medicine 202523.9.2025 13:00:00 CEST | Press Invitation
The Nobel Prize in Physiology or Medicine 2025 will be announced on Monday October 6 at 11.30 am CEST (at the earliest).
How mutations in bodily tissues affect ageing20.8.2025 11:00:00 CEST | Pressmeddelande
Two new studies from Karolinska Institutet in Sweden have investigated how mutations that occur in muscles and blood vessels over time can affect ageing. The studies, which are published in Nature Aging, show that such mutations can reduce muscle strength and accelerate blood vessel ageing. The results can be of significance to the treatment of age-related diseases.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom